SCHEMBL20820175

SCHEMBL20820175

CC1(C)C(Cn2ccc(N)nc2=O)O[C@H](CO)[C@H]1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.53
▸ PDE4D Q08499 1/20 0.53
▸ SLC29A1 Q99808 1/20 0.53
▸ LMNA P02545 5/20 0.50
▸ MTOR P42345 2/20 0.50
▸ THRB P10828 1/20 0.50
▸ MDM2 Q00987 1/20 0.50
▸ NCOA1 Q15788 1/20 0.50
▸ NCOA3 Q9Y6Q9 1/20 0.50
▸ FGFR1 P11362 3/20 0.41
▸ CACNA1F O60840 2/20 0.40
▸ ALB P02768 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ CACNA1D Q01668 2/20 0.40
▸ CACNA1S Q13698 2/20 0.40
▸ CACNA1C Q13936 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ SLC22A6 Q4U2R8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17211614 0.85 PDE3A (0.65) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL22236659 0.81 PDE3A (0.49) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL12966916 0.79 PDE3A (0.74) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL19187803 0.79 PDE3A (0.74) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL10571048 0.79 LMNA (0.56) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL8923841 0.78 LMNA (0.66) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL7180 0.78 LMNA (0.66) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL3141 0.78 LMNA (0.66) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL20820176 0.78 PDE3A (0.46) PDE3APDE4DSLC29A1LMNAMTOR
Hydrochloric Acid SCHEMBL339190 0.77 LMNA (0.64) PDE3APDE4DSLC29A1LMNAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10231986-B2 Amino acid phosphoramidate pronucleotides of 2′-cyano, azido and amino nucleosides for the treatment of HCV IDENIX PHARMACEUTICALS LLC (US) 2019-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10231986-B2 Amino acid phosphoramidate pronucleotides of 2′-cyano, azido and amino nucleosides for the treatment of HCV PNP, RNGTT, NSUN2 PDE3A 2273/4885PDE4D 3475/4885SLC29A1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback